⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara Nigel G. Maher Alison J. Potter Elizabeth C. Paver Jordan W. Conway Serigne Lo Andrew J. Colebatch Georgina V. Long James S. Wilmott Richard A. Scolyer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Low bivariate genomic model scores (<0.1) were associated with benign dermal nevi.
Examples of benign lesions NAE79 and NAE52, showing traits of solar elastosis.
The genomic test aims to stratify malignancy risk in primary melanocytic tumors.
Identifying benign tumors can reduce unnecessary interventions and anxiety for patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Validation shows low genomic scores in dermal nevi indicate lower malignancy risk, implying test utility.

Abstract

Examples of two dermal nevi (A – NAE79, B – NAE52) with solar elastosis and low bivariate genomic model scores (<0.1).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5d0 https://doi.org/10.1158/1078-0432.30029216

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
2Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
3Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
4Table S8 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
5Figure S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
6Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
7Figure S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
8Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025